Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6602999.pdf
Reference26 articles.
1. Basaran M, Bavbek SE, Gullu I, Demirelli F, Sakar B, Tenekeci N, Altun M, Yalcin S, Onat H (2002) A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother 14: 207–213
2. Baselga J (2000) New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1: 12–21
3. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumour types. J Clin Oncol 20: 4292–4302
4. Clark JI, Hofmeister C, Choudhury A, Matz G, Collins S, Bastian R, Melian E, Emami B, Petruzzelli G (2001) Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 92: 2334–2340
5. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003a) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980–1987
Cited by 84 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synergistic Potential of Methotrexate and Gefitinib: A Promising Palliative Approach for Advanced and Recurrent Head and Neck Cancers;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024
2. Spray-dried microparticles of encapsulated gefitinib for slow-release localized treatment of periodontal disease;International Journal of Pharmaceutics;2023-07
3. HPV16 status predicts potential protein biomarkers and therapeutics in head and neck squamous cell carcinoma;Virology;2023-05
4. Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer;The Cancer Journal;2022-09
5. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;Cancer Medicine;2021-09-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3